Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print]

PMID:
30039576
2.

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.

Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M.

Am J Hematol. 2018 Jul 9. doi: 10.1002/ajh.25206. [Epub ahead of print] No abstract available.

PMID:
29984867
3.

Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.

Mauro FR, Caputo MD, Rosati S, Pepe S, De Benedittis D, De Luca ML, Foà R.

Expert Rev Hematol. 2018 Aug;11(8):601-611. doi: 10.1080/17474086.2018.1495557. Epub 2018 Jul 18.

PMID:
29969322
4.

Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.

Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W.

Blood. 2018 Aug 2;132(5):547-550. doi: 10.1182/blood-2018-03-835413. Epub 2018 Jun 13. No abstract available.

PMID:
29898955
5.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R.

Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15405. [Epub ahead of print] No abstract available.

PMID:
29785734
6.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

7.

Gene mutations in lenalidomide-treated CLL.

Mauro FR, Foà R.

Blood. 2018 Apr 19;131(16):1769-1771. doi: 10.1182/blood-2018-02-830406. No abstract available.

PMID:
29674351
8.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A.

Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

PMID:
29611195
9.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
10.

Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation.

Campennì A, Ruggeri RM, Siracusa M, Pignata SA, Di Mauro F, Vento A, Trimarchi F, Baldari S.

J Endocrinol Invest. 2018 Mar 16. doi: 10.1007/s40618-018-0864-6. [Epub ahead of print]

PMID:
29549631
11.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Mar 7. doi: 10.1002/hon.2503. [Epub ahead of print] Review.

PMID:
29512173
12.

Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index.

Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, Scarpi E, Di Mauro F, Rossi A, Matteucci F, Paganelli G.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):923-930. doi: 10.1007/s00259-017-3925-8. Epub 2018 Feb 1.

PMID:
29387927
13.

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R.

Ann Oncol. 2018 Apr 1;29(4):966-972. doi: 10.1093/annonc/mdy021.

PMID:
29365086
14.

Are pre-terms born timely and right immunized? Results of an Italian cohort study.

Laforgia N, Di Mauro A, Bianchi FP, Di Mauro F, Zizzi A, Capozza M, Intini S, Gallone MS, Tafuri S.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1398-1402. doi: 10.1080/21645515.2018.1428509. Epub 2018 Feb 15.

15.

White Matter Microstructural Changes Following Quadrato Motor Training: A Longitudinal Study.

Piervincenzi C, Ben-Soussan TD, Mauro F, Mallio CA, Errante Y, Quattrocchi CC, Carducci F.

Front Hum Neurosci. 2017 Dec 7;11:590. doi: 10.3389/fnhum.2017.00590. eCollection 2017.

16.

Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.

Mauro FR, Foà R.

Lancet Oncol. 2018 Jan;19(1):7-8. doi: 10.1016/S1470-2045(17)30910-5. Epub 2017 Dec 12. No abstract available.

PMID:
29246804
17.

Analysis of area level and unit level models for small area estimation in forest inventories assisted with LiDAR auxiliary information.

Mauro F, Monleon VJ, Temesgen H, Ford KR.

PLoS One. 2017 Dec 7;12(12):e0189401. doi: 10.1371/journal.pone.0189401. eCollection 2017.

18.

Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Am J Hematol. 2018 Feb;93(2):E35-E37. doi: 10.1002/ajh.24960. Epub 2017 Nov 23. No abstract available.

PMID:
29098721
19.

Time Perception and the Experience of Time When Immersed in an Altered Sensory Environment.

Glicksohn J, Berkovich-Ohana A, Mauro F, Ben-Soussan TD.

Front Hum Neurosci. 2017 Oct 6;11:487. doi: 10.3389/fnhum.2017.00487. eCollection 2017.

20.

Clinical relevance of silent red blood cell autoantibodies.

Mauro FR, Trastulli F, Alessandri C, Valesini G, Giovannetti G, Riemma C, Porrazzo M, Pepe S, Colafigli G, Caputo MD, De Propris MS, Guarini AR, Girelli G, Coluzzi S, Foà R.

Haematologica. 2017 Dec;102(12):e473-e475. doi: 10.3324/haematol.2017.177675. Epub 2017 Sep 21. No abstract available.

21.

Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.

Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R.

Leukemia. 2018 Feb;32(2):543-546. doi: 10.1038/leu.2017.292. Epub 2017 Sep 19. No abstract available.

PMID:
28924243
22.

Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.

Vigna E, Martino B, Bacci F, Recchia AG, Mendicino F, Morelli R, Mauro FR, Musolino C, Greco R, Lucia E, Sabattini E, Morabito F, Gentile M.

Chemotherapy. 2017;62(6):350-352. doi: 10.1159/000477796. Epub 2017 Jul 26.

23.

Increased Alpha Band Functional Connectivity Following the Quadrato Motor Training: A Longitudinal Study.

Lasaponara S, Mauro F, Carducci F, Paoletti P, Tombini M, Quattrocchi CC, Mallio CA, Errante Y, Scarciolla L, Ben-Soussan TD.

Front Hum Neurosci. 2017 Jun 12;11:282. doi: 10.3389/fnhum.2017.00282. eCollection 2017.

24.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

25.

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

26.

Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.

Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A, Uccello G, Petrungaro A, Ronco F, Raponi S, Nanni M, Neri A, Ferrarini M, Guarini AR, Foà R, Gentile M.

Leuk Res. 2017 Jun;57:65-71. doi: 10.1016/j.leukres.2017.02.011. Epub 2017 Feb 27.

PMID:
28292720
27.

Another treatment option for relapsed or refractory chronic lymphocytic leukaemia.

Mauro FR.

Lancet Oncol. 2017 Mar;18(3):270-271. doi: 10.1016/S1470-2045(16)30667-2. Epub 2017 Jan 28. No abstract available.

PMID:
28139406
28.

Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.

Mauro FR, Carella AM, Molica S, Paoloni F, Liberati AM, Zaja F, Belsito V, Cortellezzi A, Rizzi R, Tosi P, Spriano M, Ferretti A, Nanni M, Marinelli M, De Propris MS, Orlando SM, Vignetti M, Cuneo A, Guarini AR, Foà R.

Leuk Lymphoma. 2017 Jul;58(7):1640-1647. doi: 10.1080/10428194.2016.1258698. Epub 2016 Nov 23.

PMID:
27881039
29.

Management of elderly and unfit patients with chronic lymphocytic leukemia.

Mauro FR, Salaroli A, Caputo MD, Colafigli G, Petrucci L, Campanelli M, Ferretti A, Guarini AR, Foà R.

Expert Rev Hematol. 2016 Dec;9(12):1165-1175. Epub 2016 Nov 21. Review.

PMID:
27796157
30.

Association of parathyroid carcinoma and thyroid disorders: A clinical review.

Campennì A, Giovinazzo S, Pignata SA, Di Mauro F, Santoro D, Curtò L, Trimarchi F, Ruggeri RM, Baldari S.

Endocrine. 2017 Apr;56(1):19-26. doi: 10.1007/s12020-016-1147-7. Epub 2016 Oct 15. Review.

PMID:
27744598
31.

Robotic Near-Total Pancreatectomy for Nesidioblastosis after Bariatric Surgery.

Macedo AL, Hidal JT, Marcondes W, Mauro FC.

Obes Surg. 2016 Dec;26(12):3082-3083.

32.

Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Gentile M, Shanafelt TD, Rossi D, Laurenti L, Mauro FR, Molica S, Cutrona G, Uccello G, Campanelli M, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Blood. 2016 Oct 20;128(16):2093-2095. doi: 10.1182/blood-2016-07-728261. Epub 2016 Aug 22. No abstract available.

33.

Point of Care Measurement of Lactate.

Di Mauro FM, Schoeffler GL.

Top Companion Anim Med. 2016 Mar;31(1):35-43. doi: 10.1053/j.tcam.2016.05.004. Epub 2016 May 21. Review.

PMID:
27451047
34.

Management of seizure on Postpartum Day 8: A case report of late postpartum eclampsia.

Sigismondi C, Valsecchi L, Gerevini S, Falini A, Mauro F, Candiani M.

Taiwan J Obstet Gynecol. 2016 Jun;55(3):444-5. doi: 10.1016/j.tjog.2016.04.025. No abstract available.

35.

Non-18F-FDG PET/CT in the management of patients affected by HNC: state-of-the-art.

Quartuccio N, Caobelli F, Di Mauro F, Cammaroto G; Young AIMN Working Group.

Nucl Med Commun. 2016 Sep;37(9):891-8. doi: 10.1097/MNM.0000000000000530. Review.

PMID:
27139114
36.

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F.

Eur J Cancer. 2016 Jun;60:154-65. doi: 10.1016/j.ejca.2016.03.069. Epub 2016 Apr 27.

PMID:
27127905
37.

Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic work-up.

Mauro FR, Coluzzi S, Paoloni F, Trastulli F, Armiento D, Ferretti A, Giovannetti G, Colafigli G, Molica M, la Rocca U, De Propris MS, Caronna R, Morano G, Guarini A, Girelli G, Foà R.

Am J Hematol. 2016 Jul;91(7):E319-20. doi: 10.1002/ajh.24379. Epub 2016 Apr 24. No abstract available.

38.

Mean Platelet Volume, Vitamin D and C Reactive Protein Levels in Normal Weight Children with Primary Snoring and Obstructive Sleep Apnea Syndrome.

Zicari AM, Occasi F, Di Mauro F, Lollobrigida V, Di Fraia M, Savastano V, Loffredo L, Nicita F, Spalice A, Duse M.

PLoS One. 2016 Apr 7;11(4):e0152497. doi: 10.1371/journal.pone.0152497. eCollection 2016.

39.

Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.

Laurenti L, Autore F, Innocenti I, D'Arena G, Coscia M, Mondello P, Chiusolo P, Bellesi S, Efremov DG, Sica S, Mauro FR.

Leuk Lymphoma. 2016 Oct;57(10):2429-31. doi: 10.3109/10428194.2015.1137293. Epub 2016 Jan 27. No abstract available.

PMID:
26818825
40.

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.

Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F.

Leukemia. 2016 Jun;30(6):1440-3. doi: 10.1038/leu.2015.333. Epub 2015 Dec 9. No abstract available.

PMID:
26648537
41.

Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.

Del Giudice I, Marinelli M, Wang J, Bonina S, Messina M, Chiaretti S, Ilari C, Cafforio L, Raponi S, Mauro FR, Di Maio V, De Propris MS, Nanni M, Ciardullo C, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R.

Br J Haematol. 2016 Feb;172(3):371-383. doi: 10.1111/bjh.13859. Epub 2015 Nov 24.

42.

A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV-D-J rearrangements and BRAF-V600E mutation: lack of evidence for a common origin.

Cavalli M, Ilari C, Del Giudice I, Marinelli M, Della Starza I, De Propris MS, De Novi LA, Nunes V, Cafforio L, Raponi S, Mancini F, Mauro FR, Tiacci E, Falini B, Guarini A, Foà R.

Br J Haematol. 2016 Jul;174(2):329-31. doi: 10.1111/bjh.13770. Epub 2015 Oct 12. No abstract available.

PMID:
26455504
43.

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, Del Poeta G, Mauro FR, Cortelezzi A, Borza PA, Ghio F, Mondello P, Murru R, Gozzetti A, Cariccio MR, Piccirillo N, Boncompagni R, Cantonetti M, Principe MI, Reda G, Bongarzoni V, Cervetti G, Pitini V, Foà R, Sica S, D'Arena G.

Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.

PMID:
26307523
44.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

45.

A bidirectional link between brain oscillations and geometric patterns.

Mauro F, Raffone A, VanRullen R.

J Neurosci. 2015 May 20;35(20):7921-6. doi: 10.1523/JNEUROSCI.0390-15.2015.

46.

The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Cammaroto G, Quartuccio N, Sindoni A, Di Mauro F, Caobelli F; Young AIMN Working Group.

Eur Arch Otorhinolaryngol. 2016 Aug;273(8):1961-73. doi: 10.1007/s00405-015-3651-4. Epub 2015 May 14. Review.

PMID:
25971995
47.

Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.

Gentile M, Cutrona G, Molica S, Ilariucci F, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Lionetti M, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Musto P, Federico M, Neri A, Ferrarini M, Morabito F.

Eur J Haematol. 2016 Jan;96(1):36-45. doi: 10.1111/ejh.12545. Epub 2015 Mar 31.

PMID:
25753656
48.

Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.

Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R.

Leukemia. 2015 Jun;29(6):1360-5. doi: 10.1038/leu.2015.21. Epub 2015 Feb 4.

PMID:
25650091
49.

Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.

Tavolaro S, Colombo T, Chiaretti S, Peragine N, Fulci V, Ricciardi MR, Messina M, Bonina S, Brugnoletti F, Marinelli M, Di Maio V, Mauro FR, Del Giudice I, Macino G, Foà R, Guarini A.

Genes Chromosomes Cancer. 2015 Apr;54(4):222-34. doi: 10.1002/gcc.22236. Epub 2015 Feb 2.

PMID:
25645730
50.

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.

Cuneo A, Marchetti M, Barosi G, Billio A, Brugiatelli M, Ciolli S, Laurenti L, Mauro FR, Molica S, Montillo M, Zinzani P, Tura S.

Leuk Res. 2014 Nov;38(11):1269-77. doi: 10.1016/j.leukres.2014.06.017. Epub 2014 Jul 7.

PMID:
25063524

Supplemental Content

Support Center